Kindred Biosciences – Consensus Indicates Potential 117.8% Upside

Broker Ratings

Kindred Biosciences with ticker code (KIN) have now 7 analysts covering the stock with the consensus suggesting a rating of ‘Buy’. The target price ranges between 14 and 9 with a mean TP of 10.89. Now with the previous closing price of 5 this would imply there is a potential upside of 117.8%. The 50 day moving average now sits at 4.6 and the 200 day moving average is 4.23. The market cap for the company is $197m. Company Website:

Kindred Biosciences, a biopharmaceutical company, is developing biologics that focus on the lives of pets. The company has a pipeline of novel biologics in development across various therapeutic classes and intellectual property portfolio. Its programs under development include interleukin-31 and interleukin-4R for canine atopic dermatitis; KIND-030 for parvovirus in dogs; KIND-510a for the control of non-regenerative anemia in cats; anti-TNF antibody for inflammatory bowel disease in dogs; and other biologics candidates. The company was founded in 2012 and is headquartered in Burlingame, California.

You can now share this on Stocktwits, just click the logo below and add the ticker in the text to be seen.

Share on Stocktwits

Good news travels fast (but only if you make that happen). Share on:

Share on twitter
Share on linkedin
Share on facebook
Share on email
Share on reddit

AIM All Share Index